Antigenics

Dr. Garo Armen, a scientist and entrepreneur, founded Antigenics in 2001. He previously founded the biotech company Agenus (formerly Antigenics, Inc.). His scientific background shapes the firm's investment focus on life sciences.

The firm invests in healthcare and technology assets, including public equities and private placements. It focuses on translational medicine and orphan drug development, but also holds a diversified portfolio of marketable securities. Strategy involves direct equity stakes and partnerships with research institutions.

Antigenics appears to operate more like a hybrid entity. Although founded as a biotech company, it now functions as an investment vehicle for its principals. It does not publicly market itself as a family office or a traditional venture capital firm, and its capital base is not open to external investors.

Given Dr. Armen's network in biotech and academia, deal flow likely comes from scientific and industry contacts. The firm may also leverage relationships from its earlier clinical-stage operations to access early-stage life sciences opportunities.

Sector focus is primarily healthcare, including biotechnology, orphan drugs, and medical technology. The firm has also shown interest in broader technology investments, though the exact composition of its portfolio is not publicly detailed.

No recent investment activity is publicly documented. The firm has limited transparency regarding its current portfolio or new deals. Prior major events include the restructuring of the company following the failure of its lead cancer vaccine candidate in 2016.

Garo Armen founded both entities. Antigenics originally operated as a publicly traded biotech company before renaming to Agenus in 2011. Antigenics, as the investment entity, manages assets that were retained after that corporate restructuring.